Kurt Wheeler has been Managing Director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct investment and industry experience within the healthcare sector. Mr. Wheeler was founder and CEO of InControl (NASDAQ:INCL), a medical device company sold to Guidant. Prior to founding InControl he was a Principal with the Mayfield Fund focused on healthcare investing. Mr. Wheeler began his career with Elli Lilly & Co. Mr. Wheeler holds a BA from Brigham Young University, and a MBA from Northwestern University’s Kellogg School. Mr. Wheeler represents Clarus Ventures on the Board of Directors of Avillion, Globus Medical Inc.(NYSE: GMED), Flowonix, and SFJ Pharmaceuticals. Previous directorships include Cardiac Dimensions, CHF Solutions (acquired by Gambro), Hemosense (AMEX: HEM) acquired by Inverness Medical, Intrathrerapeutics acquired by Sulzer Medica, Eyetech Pharmaceuticals (NASDAQ: EYET), SenoRx (NASDAQ: SENO) acquired by CR Bard, Neuromed Pharmaceuticals (NASDAQ: ZLCS), Somaxon Pharmaceuticals (NASDAQ: SOMX), and Zogenix (NASDAQ: ZGNX).